Medical research: seeking the right company
16 October, 2014 by Graeme O'NeillAustralia excels in biomedical research but sucks at commercialisation. Professor Frank Gannon says that needs to change.
CSL launches $950m share buyback
15 October, 2014 by Dylan Bushell-EmblingCSL (ASX:CSL) chairman Professor John Shine used his AGM address to announce a $950m share buyback and detail the company's achievements over the past 12 months.
Manufacturing matters to Australia
14 October, 2014With manufacturing at the forefront of public policy discourse, AusBiotech is to host the inaugural Advanced Manufacturing Summit to facilitate discussions to drive change and embrace the opportunities for Australia's current and future manufacturers and their supply chains.
Eye Co gets European patent for eye disease drug
13 October, 2014 by Dylan Bushell-EmblingMelbourne's Eye Co has picked up a European patent covering a new class of steroids to treat diabetic eye disease.
Analytica raising $4m for PeriCoach launch
10 October, 2014 by Dylan Bushell-EmblingAnalytica (ASX:ALT) has secured a CE Mark for its PeriCoach device and has launched an up to $4m capital raising to help fund marketing ahead of its formal launch in Australia.
Annual Report 2014: AusBiotech "facilitating global development"
09 October, 2014The AusBiotech Annual Report 2014 is now available, detailing how AusBiotech is delivering on its plan to facilitate global development of the Australian life sciences industry.
BVA's bionic eye implant shown to be safe
09 October, 2014 by Dylan Bushell-EmblingBionic Vision Australia's (BVA) prototype 24-channel percutaneous connector implant was found to be safe during its first clinical trial in retinosis pigmentosa.
Antara Lifesciences raises $7m in IPO
07 October, 2014 by Dylan Bushell-EmblingAntara Lifesciences (ASX:ANR) will use the proceeds from its recent IPO to help commercialise non-antibiotic diarrhoea treatment Detach in livestock animals and develop a version for humans.
Public forum on biotech's role in treatment of dementias and Alzheimer's
07 October, 2014With more than 332,000 Australians currently living with dementia and this figure expected to increase to 400,000 in less than a decade, AusBiotech will hold a free public forum with Australia's leading experts discussing what the future holds for the treatment and prevention of dementias and Alzheimer's and the supports available for those affected.
Phosphagenics beats market leader in acne trial
07 October, 2014 by Dylan Bushell-EmblingPhosphagenics' TPM-Tretinoin drug candidate outperformed the market leader during a phase II trial, with the results suggesting that TPM itself has inherent anti-acne qualities.
VivaGel condoms to go on sale this month
03 October, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) and partner Ansell (ASX:ANN) have registered their VivaGel coated condom on the ARTG and plan to launch the product in Australia this month.
MCRI, Curve Tomorrow win top award in Silicon Valley
02 October, 2014 by Dylan Bushell-EmblingMurdoch Childrens Research Institute and Curve Tomorrow have won first place in the Launch! session of the Annual Fall Health 2.0 conference in California.
New report on the uptake of assistive health technologies in Australia
02 October, 2014Australia needs to actively drive the uptake of assistive healthcare technologies to allow people to stay at home longer and live more independently, according to a new Australian Council of Learned Academies (ACOLA) report.
Merck buying Sigma-Aldrich for $19.6bn
01 October, 2014 by Dylan Bushell-EmblingGermany's Merck has arranged to acquire chemical and biochemical supplier Sigma-Aldrich in a deal worth US$17bn.
Queensland Government responds in support of review of Gene Technology Act
30 September, 2014The Queensland Government's response to the recommendations of the review of the operation of the Gene Technology Act 2001 (Qld) has been released. The government said its response to the review recommendations was prepared in consultation with relevant departments "who generally support the findings of the review".
